ArticleAmerican journal of translational research2025
Pidotimod plus recombinant human interferon α-2b suppository boosts HPV clearance in high-risk patients following loop electrosurgical excision procedure.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reducing HPV Viral Burden in Men: A Synergistic Approach Using Pidotimod and Prophylactic Vaccination.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess human papillomavirus (HPV) negative conversion, vaginal microecological recovery, and serum inflammatory factor levels in patients with high-risk HPV infection treated with pidotimod (PDT) plus recombinant human interferon α-2b (rh-IFN-α2b) suppository after loop electrosurgical excision procedure (LEEP).
methodsA total of 97 patients with high-risk HPV infection who underwent LEEP from March 2020 to May 2023 were retrospectively selected. Among these cases, 45 treated with rh-IFN-α2b suppository were assigned as control group, while the other 52 treated with PDT + rh-IFN-α2b suppository were assigned as combined group. HPV negative conversion, side effects (fever, nausea, abdominal discomfort, and vaginal burning sensation), vaginal microecology recovery (vaginal pH, Nugent score), and serum inflammatory markers (interleukin [IL]-4, IL-12, and interferon [IFN]-γ) were compared between the two groups. Furthermore, univariate and multivariate analyses were performed to identify factors associated with failure to achieve negative conversion.
resultsThe combined group demonstrated a higher HPV negative conversion rate, treatment response rate, and vaginal microecological recovery rate (lower vaginal pH and Nugent score) compared to the control group. Also, post-treatment IL-4 levels were lower, while IL-12 and IFN-γ were higher in the combined group. The side effects in the two groups were similar. Univariate and multivariate analyses revealed that HPV type and treatment modality were associated with HPV negative conversion failure, but were not independent predictors.
conclusionsPDT plus rh-IFN-α2b suppository can effectively improve HPV negative conversion, accelerate vaginal microecology recovery, and modulate serum inflammatory responses in high-risk HPV patients after LEEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.